Topoisomerase II-α is a molecular target of anthracyclines; several studies have suggested that topoisomerase II-α expression is related to response to anthracycline treatment. The objective of this study was to evaluate whether topoisomerase II-α overexpression predicts response to anthracycline treatment in locally advanced breast cancer patients.
This was a prospective study including 50 patients with primary non-metastatic locally advanced breast cancer according to American Joint Committee For Cancer Staging (T3-4; N0-3) who were treated between January 2012 and June 2012 at the Clinical Oncology Department, Tanta University Hospital. Topoisomerase II-α, HER2, estrogen receptor (ER), progesterone receptor (PR) expression and Ki-67 were evaluated by immunohistochemistry in formalin-fixed, paraffin-embedded breast tumors from 50 patients presenting with locally advanced breast cancer.
Tumors were from 50 patients; 45 (90%) showed topoisomerase II-α overexpression, 34 (68%) were ER positive, 32 (64%) were PR positive,10 (20%) showed HER2 overexpression, and 16 (32%) showed high KI 67. Significant correlation was seen between clinical and pathological response with topo IIA, HER2 and KI-67. p value (≤0.001), (0.005) and (0.015), respectively. 1-Responders: Clinical (CR): 3 patients had co-expression of topo II and HER2, hormone receptor negative and high KI-67. Clinical (PR): 43 patients, the majority, showed topo IIA overexpression. 2-Non-responders: 4 (8%) patients had negative TOPOII/HER2, low KI-67, and 2 were hormone receptor positive, and another 2 were hormone receptor negative.
Our data support a correlation between topoisomerase II-α expression in locally advanced breast cancer patients and improved clinical benefit with neoadjuvant anthracycline-based therapy.
The role of Topoisomerase II-α (TOPO IIA) as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer.
background,
Topoisomerase II-α is a molecular target of anthracyclines; several studies have suggested that topoisomerase II-α expression is related to response to anthracycline treatment. The objective of this study was to evaluate if topoisomerase II-α overexpression predicts response to anthracycline treatment in locally advanced breast cancer patients.
MATERIAL AND METHODS:
This prospective study included 50 patients with primary non metastatic locally advanced breast cancer according to American Joint Committee For Cancer Staging(T3-4;N0-3)were treated between January 2012 and Jaune 2012 at Clinical Oncology Department, Tanta University Hospital.
Topoisomerase II-α, HER2, estrogen receptor (ER) , progesterone receptor (PR) expression and KI-67 were evaluated by immunohistochemistry in formalin-fixed, paraffin-embedded breast tumors from 50 patients presenting with locally advanced breast cancer.
RESULTS:
Tumors from 50 patients, 45 (90%) showed topoisomerase II-α overexpression, patients 34 (68%) for ER positive, 32 (64%) for PR positive and 10 (20%) for HER2 overexpression and 16 (32%) for high KI 67.
Significant correlation between clinical and pathological response with topo IIA, HER2 and KI-67. p value (≤0.001), (0.005) and (0.015) respectively.
1-Responders :
Clinical (CR): 3 patients had co-expression of topo II and HER2, hormonal receptor negative and high KI-67.
Clinical(PR):43 patients majority of them had topo IIA overexpression .fig(9-10)
2-Non responders :
4(8%) patients all had negative (TOPOII/HER2), low KI-67and 2 had hormonal receptor positive and another 2 had hormonal receptor negative.
CONCLUSIONS:
Our data support a correlation between topoisomerase II-α expression in locally advanced breast cancer patients and improved clinical benefit with neoadjuvant anthracyclines based therapy.
Tanta University, Clinical Oncology Department
N/A
All authors have declared no conflicts of interest.